非酒精性脂肪性肝病中纤维化分期增加死亡风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项成人非酒精性脂肪性肝病队列研究、共1,495例患者和17,452患者年随访,以纤维化0期为参照,量化各纤维化分期的全因和肝病相关死亡风险。结果显示全因死亡风险随纤维化分期增加而升高,肝病相关死亡风险呈指数级增加。
要点
- 与0期相比,纤维化1、2、3、4期的全因死亡风险比分别为1.58、2.52、3.48、6.40。
- 肝病相关死亡风险随纤维化分期增加呈指数级升高,4期死亡风险比为42.30。
- 研究局限性包括无法校正合并症或人口学因素,以及参照组包含无纤维化的单纯性脂肪变和非酒精性脂肪性肝炎患者。
核心结论
- 肝病相关死亡风险随纤维化分期增加呈指数级升高,这些数据对评估各分期的效用及纤维化消退(从一个分期到另一个分期)的获益具有重要意义。
研究设计与样本
- 系统综述与荟萃分析,纳入5项报告纤维化分期(0-4)特异性死亡率的成人非酒精性脂肪性肝病队列研究,共1,495例患者,随访17,452患者年;以纤维化0期为参照人群,按PRISMA声明报告。
主要发现
- 与无纤维化(0期)相比,纤维化1期全因死亡风险比MRR=1.58(95%CI 1.19-2.11)。
- 纤维化2期全因死亡风险比MRR=2.52(95%CI 1.85-3.42)。
- 纤维化3期全因死亡风险比MRR=3.48(95%CI 2.51-4.83)。
- 纤维化4期全因死亡风险比MRR=6.40(95%CI 4.11-9.95)。
- 肝病相关死亡风险:1期MRR=1.41(95%CI 0.17-11.95),2期MRR=9.57(95%CI 1.67-54.93),3期MRR=16.69(95%CI 2.92-95.36),4期MRR=42.30(95%CI 3.51-510.34)。
关键数值与推荐
- 全因死亡风险随纤维化分期增加而升高:1期MRR=1.58(95%CI 1.19-2.11),2期MRR=2.52(95%CI 1.85-3.42),3期MRR=3.48(95%CI 2.51-4.83),4期MRR=6.40(95%CI 4.11-9.95)。
- 肝病相关死亡风险随纤维化分期增加呈指数级升高:1期MRR=1.41(95%CI 0.17-11.95),2期MRR=9.57(95%CI 1.67-54.93),3期MRR=16.69(95%CI 2.92-95.36),4期MRR=42.30(95%CI 3.51-510.34)。
局限性
- 研究局限性包括无法校正已知影响非酒精性脂肪性肝病纤维化进展的合并症或人口学因素。
- 参照比较组纳入了无纤维化的单纯性脂肪变和非酒精性脂肪性肝炎患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage-specific risk of all-cause and liver-related mortality in NAFLD. Through a systematic review and meta-analysis, we identified five adult NAFLD cohort studies reporting fibrosis stage-specific mortality (0-4). Using fibrosis stage 0 as a reference population, fibrosis stage-specific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all-cause and liver-related mortality were estimated. The study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Included were 1,495 NAFLD patients with 17,452 patient years of follow-up. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all-cause mortality, and this risk increased with increases in the stage of fibrosis: stage 1, MRR = 1.58 (95% CI 1.19-2.11); stage 2, MRR = 2.52 (95% CI 1.85-3.42); stage 3, MRR = 3.48 (95% CI 2.51-4.83); and stage 4, MRR = 6.40 (95% CI 4.11-9.95). The results were more pronounced as the risk of liver-related mortality increased exponentially with each increase in the stage of fibrosis: stage 1, MRR = 1.41 (95% CI 0.17-11.95); stage 2, MRR = 9.57 (95% CI 1.67-54.93); stage 3, MRR = 16.69 (95% CI 2.92-95.36); and stage 4, MRR = 42.30 (95% CI 3.51-510.34). Limitations of the study include an inability to adjust for comorbid conditions or demographics known to impact fibrosis progression in NAFLD and the inclusion of patients with simple steatosis and nonalcoholic steatohepatitis without fibrosis in the reference comparison group. CONCLUSION: The risk of liver-related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (Hepatology 2017;65:1557-1565).
引用
- Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017. PMID: 28130788. doi:10.1002/hep.29085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。